Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eleven-year management of prostate cancer patients on active surveillance: what have we learned?
Marenghi C, Alvisi MF, Palorini F, Avuzzi B, Badenchini F, Bedini N, Bellardita L, Biasoni D, Bosetti D, Casale A, Catanzaro M, Colecchia M, De Luca L, Donegani S, Dordoni P, Lanocita R, Maffezzini M, Magnani T, Menichetti J, Messina A, Morlino S, Paolini B, Rancati T, Stagni S, Tesone A, Torelli T, Tulli Baldoin E, Vaiani M, Villa S, Villa S, Zaffaroni N, Nicolai N, Salvioni R, Valdagni R. Marenghi C, et al. Among authors: paolini b. Tumori. 2017 Sep 18;103(5):464-474. doi: 10.5301/tj.5000649. Epub 2017 Jun 14. Tumori. 2017. PMID: 28623636 Free PMC article.
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment.
Giannatempo P, Paolini B, Miceli R, Raggi D, Nicolai N, Farè E, Catanzaro M, Biasoni D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A. Giannatempo P, et al. Among authors: paolini b. J Urol. 2013 Nov;190(5):1919-24. doi: 10.1016/j.juro.2013.04.057. Epub 2013 Apr 25. J Urol. 2013. PMID: 23624209
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy.
Necchi A, Giannatempo P, Paolini B, Lo Vullo S, Marongiu M, Farè E, Raggi D, Nicolai N, Piva L, Catanzaro M, Biasoni D, Torelli T, Stagni S, Maffezzini M, Gianni AM, De Braud F, Mariani L, Sonpavde G, Colecchia M, Salvioni R. Necchi A, et al. Among authors: paolini b. Clin Genitourin Cancer. 2015 Apr;13(2):171-7.e1. doi: 10.1016/j.clgc.2014.08.002. Epub 2014 Aug 8. Clin Genitourin Cancer. 2015. PMID: 25193365
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.
Necchi A, Lo Vullo S, Mariani L, Raggi D, Giannatempo P, Calareso G, Togliardi E, Crippa F, Di Genova N, Perrone F, Colecchia M, Paolini B, Pelosi G, Nicolai N, Procopio G, Salvioni R, De Braud FG. Necchi A, et al. Among authors: paolini b. Invest New Drugs. 2016 Apr;34(2):236-42. doi: 10.1007/s10637-016-0328-9. Epub 2016 Feb 12. Invest New Drugs. 2016. PMID: 26873642 Clinical Trial.
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure.
Necchi A, Anichini A, Raggi D, Giannatempo P, Magazzù D, Nicolai N, Colecchia M, Paolini B, Coradeschi E, Tassi E, Grazia G, Mortarini R, Calareso G, De Fato R, Togliardi E, Crippa F, Salvioni R, Valagussa P, Gianni AM. Necchi A, et al. Among authors: paolini b. Clin Genitourin Cancer. 2016 Aug;14(4):261-264.e4. doi: 10.1016/j.clgc.2016.03.020. Epub 2016 Mar 24. Clin Genitourin Cancer. 2016. PMID: 27105722 No abstract available.
Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
De Gobbi A, Biasoni D, Catanzaro M, Nicolai N, Piva L, Stagni S, Torelli T, Procopio G, Verzoni E, Grassi P, Colecchia M, Paolini B, Spreafico C, Marchianò A, Salvioni R. De Gobbi A, et al. Among authors: paolini b. Tumori. 2018 Oct;104(5):388-393. doi: 10.5301/tj.5000596. Epub 2018 May 8. Tumori. 2018. PMID: 28085177 Clinical Trial.
104 results